secwatch.observer — SEC 8-K summary
======================================

Issuer:     ELI LILLY & Co (LLY)
CIK:        0000059478
Form:       8-K
Filed at:   2026-04-30T23:59:59+00:00
Accession:  0000059478-26-000043
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lilly Q1 revenue $19.8B (+56% YoY), raises FY guidance, FDA approves Foundayo
-----------------------------------------------------------------------------

- Q1 2026 revenue $19.8B (up 56% YoY); reported EPS $8.26 (up 170%); non-GAAP EPS $8.55.
- FY2026 revenue guidance raised to $82B-$85B; non-GAAP EPS guidance $35.50-$37.00.
- U.S. FDA approved Foundayo (orforglipron) for obesity—first GLP-1 pill without food/water restrictions.
- Acquired Orna Therapeutics, Centessa Pharmaceuticals, Kelonia Therapeutics, and Ajax Therapeutics.
- Pipeline progress: positive Phase 3 for Foundayo in T2D, Jaypirca combo in CLL, and retatrutide in T2D.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/59478/000005947826000043/0000059478-26-000043-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/59478/000005947826000043/lly-20260430.htm
  HTML page:      https://secwatch.observer/filing/0000059478-26-000043

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer